147 related articles for article (PubMed ID: 12091352)
1. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Liao AT; Chien MB; Shenoy N; Mendel DB; McMahon G; Cherrington JM; London CA
Blood; 2002 Jul; 100(2):585-93. PubMed ID: 12091352
[TBL] [Abstract][Full Text] [Related]
2. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
[TBL] [Abstract][Full Text] [Related]
3. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
4. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.
Ma Y; Carter E; Wang X; Shu C; McMahon G; Longley BJ
J Invest Dermatol; 2000 Feb; 114(2):392-4. PubMed ID: 10652004
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
6. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
[TBL] [Abstract][Full Text] [Related]
7. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
Spiekermann K; Faber F; Voswinckel R; Hiddemann W
Exp Hematol; 2002 Jul; 30(7):767-73. PubMed ID: 12135675
[TBL] [Abstract][Full Text] [Related]
8. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
9. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
10. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
Halsey CH; Gustafson DL; Rose BJ; Wolf-Ringwall A; Burnett RC; Duval DL; Avery AC; Thamm DH
BMC Vet Res; 2014 May; 10():105. PubMed ID: 24885200
[TBL] [Abstract][Full Text] [Related]
11. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Smolich BD; Yuen HA; West KA; Giles FJ; Albitar M; Cherrington JM
Blood; 2001 Mar; 97(5):1413-21. PubMed ID: 11222388
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
13. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
15. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Lin TY; Bear M; Du Z; Foley KP; Ying W; Barsoum J; London C
Exp Hematol; 2008 Oct; 36(10):1266-77. PubMed ID: 18657349
[TBL] [Abstract][Full Text] [Related]
16. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
Ma Y; Zeng S; Metcalfe DD; Akin C; Dimitrijevic S; Butterfield JH; McMahon G; Longley BJ
Blood; 2002 Mar; 99(5):1741-4. PubMed ID: 11861291
[TBL] [Abstract][Full Text] [Related]
17. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
DiNitto JP; Deshmukh GD; Zhang Y; Jacques SL; Coli R; Worrall JW; Diehl W; English JM; Wu JC
J Biochem; 2010 Apr; 147(4):601-9. PubMed ID: 20147452
[TBL] [Abstract][Full Text] [Related]
18. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.
Tsujimura T; Morimoto M; Hashimoto K; Moriyama Y; Kitayama H; Matsuzawa Y; Kitamura Y; Kanakura Y
Blood; 1996 Jan; 87(1):273-83. PubMed ID: 8547652
[TBL] [Abstract][Full Text] [Related]
20. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]